ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
S

Long-term Outcomes of Early CP CML Patients who Have Achieved CCyR but not MMR After 24 Months on Frontline Imatinib Therapy

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Sung-Huyn Kim
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Sung-Huyn Kim
0 views
January 2, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Brief Oral Communications (Clinical)
08:29
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

The Technical Decline in the Rate of CML Treatment-free Remission in…

Feat. M. Delord
06:58
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Patients’ Perspectives on the Definition of Cure in Chronic Myeloid …

Feat. G. George
08:10
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Long-term Outcomes of Early CP CML Patients who Have Achieved CCyR b…

Feat. S. Kim
06:31
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Prevalence and Outcomes of Uncommon BCR-ABL Fusion Transcripts in Pa…

Feat. Q. Jiang
05:34
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Cumulative Incidence of Treatment-free Remission (TFR) for Patients …

Feat. N. Shanmuganathan